eFFECTOR Therapeutics Company Description
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer.
The company’s lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.
It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.
It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E.
eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Craig Jalbert |
Contact Details
Address: 142 North Cedros Avenue Solana Beach, Delaware 92075 United States | |
| Phone | 858 925 8215 |
| Website | effector.com |
Stock Details
| Ticker Symbol | EFTR |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US28202V1089 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig R. Jalbert CIRA | Chief Executive Officer, President, Treasurer &Secretary, and Director |
| Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |